Ep. 4: Busting the LDL Cholesterol Myth: It is NOT What You Think — with Dr. Ernst Schaefer, Lipidologist

Is LDL cholesterol really the villain it’s made out to be? In this episode, Dr. Regina Druz sits down with lipidologist Dr. Ernst J. Schaefer — Chief Medical Officer and co-founder of Boston Heart Diagnostics and a longtime Framingham Heart Study researcher — to bust the cholesterol myth. They unpack why it’s small dense LDL, not total cholesterol, that does the most damage; how ApoB, Lp(a), and oxidized phospholipids fit in; why popular risk calculators are only about 65% accurate; and how to lower risk with the lowest effective statin dose rather than the highest.

Watch on YouTube: A video version of this episode is available on the Own Your Heart Health YouTube channel. Subscribe to be notified of new episodes.

Episode Chapters

[00:00] Introduction & Meet Dr. Ernst Schaefer
[01:30] From Mount Sinai to Framingham
[03:30] What Framingham Taught Us About Risk
[06:30] Risk in Context — and the Top Risk Factors
[10:30] Cholesterol: First Responder or Fire-Starter?
[14:00] Why Risk Calculators Are Only ~65% Accurate
[17:00] Small Dense LDL: The Most Dangerous Particle
[19:30] ApoB, Lp(a) & Oxidized Phospholipids
[24:30] The PREVENT Calculator & Its Controversy
[30:30] Calcium Score, Soft Plaque & CT Angiography
[36:00] The Dyslipidemic Triad & Insulin Resistance
[48:30] Lowering LDL: Statins, ALARA & Side Effects
[54:30] The Best Mortality Markers & Closing

Transcript

[00:00] Introduction & Meet Dr. Ernst Schaefer

Dr. Regina Druz (00:00): Welcome to Own Your Heart Health. I’m Dr. Regina Druz, your holistic cardiologist. This week we’ll dive into common heart health concerns, uncovering root causes and unpacking scientific discoveries and controversies. The information provided does not constitute medical advice. Please contact your healthcare practitioner before making any changes that may impact your health.

Dr. Regina Druz (00:30): Welcome, everybody. Today’s episode is “Busting the Cholesterol Myth — It’s Not What You Think.” I’m thrilled to have a guest whose work I’ve followed for many years and that helped shape my own thinking. Let me introduce Dr. Ernst Schaefer, Chief Medical Officer and co-founder of Boston Heart Diagnostics, a leading laboratory specializing in cardiovascular testing. Ernie, welcome to the show.

Dr. Ernst Schaefer (01:00): Thank you.

[01:30] From Mount Sinai to Framingham

Dr. Regina Druz (01:30): What led you to lipidology and to founding Boston Heart Diagnostics?

Dr. Ernst Schaefer (01:45): As a student, resident, and fellow at Mount Sinai in New York, I rotated through the coronary care unit. In my first week, three patients died despite what I thought was good care. Two had autopsies showing severe, diffuse coronary atherosclerosis — I was amazed they’d lived as long as they did. My attending, the famous cardiologist Dr. Charles Friedberg, told me we didn’t know much about the disease but that blood pressure mattered, and suggested I go read about it. That led me to the Framingham Heart Study — right where Boston Heart is now — and I’ve worked with Framingham ever since.

Dr. Ernst Schaefer (02:30): Framingham showed us the risk factors for clogged arteries: age and sex, but also high blood pressure, diabetes, smoking, high LDL cholesterol, and low HDL. Then people took a simple approach — treat those risk factors and see if it helps. It’s made a huge difference; we’ve been very successful at reducing heart disease.

[03:30] What Framingham Taught Us About Risk

Dr. Regina Druz (03:30): Framingham was famously launched after President Franklin Roosevelt’s stroke made it clear we had no framework to prevent strokes and heart attacks. Those were the years when nearly everyone smoked. How did your work expand beyond Framingham?

Dr. Ernst Schaefer (04:00): After Mount Sinai I did research at Albert Einstein on HDL particles, and at Rockefeller, where in the 1960s and ’70s they were already measuring cholesterol production versus absorption. We also knew diet mattered enormously — populations eating lots of animal fat and cholesterol, like the U.S. versus Japan, had far more heart disease. Roosevelt had severe hypertension, and Framingham taught us that of all risk factors, high blood pressure is by far the most important for stroke. For coronary disease, it’s really a combination of high LDL, diabetes, and smoking.

[06:30] Risk in Context — and the Top Risk Factors

Dr. Regina Druz (06:00): A quick note before we go on. I know the opinions on nutrition for heart health and longevity are contradictory and confusing — low-fat versus ketogenic, plus many voices for vegan or vegetarian eating. To cut through the clutter, my team and I created Holistic Heart University: on-demand courses and resources, open office hours, and a Q&A where you can put us in the hot seat. The link is in the show notes — use promo code OWNER20 for 20% off an annual subscription.

Dr. Regina Druz (06:30): What you’re really hitting at is context. Years ago, when I started in integrative cardiology, a room of functional-medicine practitioners asked whether I used statins. When I said yes, half the room backed away as if I had a contagious disease. But it isn’t yes-or-no — it’s a complex equation where we understand a person’s risk and modify it as much as we can. So, if someone only focused on lipids, how would you rank LDL among the top risk factors?

Dr. Ernst Schaefer (09:30): This is a disease of aging, more common in men, though as many women die of it about six years later on average. The most important risk factor is high blood pressure, then diabetes — though that’s only 10–15% of people — and smoking. But LDL cholesterol is what really distinguishes populations: lower LDL means much lower risk, and lowering a high LDL markedly cuts risk. It’s lifestyle, and sometimes medication. And it’s the small dense LDL that’s most atherogenic — which we can measure very easily.

[10:30] Cholesterol: First Responder or Fire-Starter?

Dr. Regina Druz (10:30): I often tell patients the coronary arteries are tiny — maybe two to two-and-a-half millimeters — and they’re constantly damaged just by the flow of blood from conception to death. I think of cholesterol as a first responder: once injury and inflammation start, cholesterol is sent to patch it up, and that’s the beginning of plaque. It’s like a firefighter arriving at a blaze — but sometimes the fire just keeps burning.

Dr. Ernst Schaefer (12:30): I’d put it a little differently. Small dense LDL deposits at sites of damage caused by high blood pressure, diabetes, and smoking. Once it’s deposited, modified, and taken up, white cells — monocytes — migrate in and become macrophages. The inflammation is really driven by the cholesterol that’s now in the artery wall. Cholesterol is essential for hormones and bile acids, but an excess in the blood is deleterious. So the factor that starts the fire burning in the wall is, in fact, cholesterol.

Dr. Regina Druz (13:30): Exactly — and the data on “LDL-years” show it’s not just the LDL level but how long it’s been elevated.

Dr. Ernst Schaefer (13:45): I agree with you a hundred percent.

[14:00] Why Risk Calculators Are Only ~65% Accurate

Dr. Ernst Schaefer (14:30): When you do a multivariate analysis of how well something predicts disease, you get a C-statistic. For the Pooled Cohort Equation it’s about 0.65 — meaning roughly 65% accurate, where 1.0 would be perfect. That tells us there are important factors not captured in the standard risk assessment.

Dr. Regina Druz (15:30): That’s so important for patients to understand. When you see your physician, we put your numbers into context drawn from very large studies — essentially referencing you against a population. But a real person in front of us may or may not fit that population. The established ASCVD Risk Estimator — about 65% accurate for predicting a 10-year risk of heart attack, stroke, or cardiovascular death — is a good place to start, even if it isn’t 90 or 100%.

[17:00] Small Dense LDL: The Most Dangerous Particle

Dr. Regina Druz (17:30): What is small dense LDL, and how does it come to be?

Dr. Ernst Schaefer (17:45): VLDL is made in the liver and converted to LDL. The higher your triglycerides, insulin resistance, and weight, the more small dense LDL you produce. Almost all the risk associated with LDL is due to small dense LDL. Only about 30% of the cholesterol is in small dense particles, but 70–80% of the particles are — and they get into the artery wall much more readily. We’ve measured their residence time with stable isotopes: about four days versus two days for larger LDL. Because they hang around longer, they’re more likely to be oxidized and taken up by macrophages, forming the fatty streak and then the plaque.

[19:30] ApoB, Lp(a) & Oxidized Phospholipids

Dr. Regina Druz (19:30): Let me back up for listeners. Cholesterol is a fatty substance, so it can’t travel alone — each particle is wrapped in a protein coat, which is why we call them lipoproteins. Picture little balls thrown at your arteries: the more balls, and the more harmful what’s inside, the more get stuck. When we measure LDL cholesterol, we measure what’s inside the ball. When we count the balls, that’s ApoB — and there’s one ApoB per LDL particle, so it’s a precise particle count. Increasingly, ApoB looks like a more predictive marker than non-HDL cholesterol. Your thoughts?

Dr. Ernst Schaefer (21:00): Yes. ApoB sits on the surface. The surface also carries phospholipids, which have fatty acids that get oxidized — and it’s the oxidized phospholipid on LDL that gets deposited. Lipoprotein(a) — a genetically determined particle — actually accepts those oxidized phospholipids, and that oxidation is very deleterious. That’s why small dense LDL and Lp(a) are both very important risk factors. At Boston Heart we also uniquely measure Lp-PLA2, the enzyme that oxidizes LDL, and the amount of oxidized phospholipid on ApoB.

Dr. Regina Druz (22:00): If we focus only on lipids, I’d say every adult should know their LDL cholesterol, ApoB, small dense LDL, and Lp(a). Those are the major, easily measurable, oxidation-related factors — and unfortunately they’re not yet part of the standardized equations, though that time is coming.

[24:30] The PREVENT Calculator & Its Controversy

Dr. Regina Druz (24:30): Risk estimation is getting more precise — I call what I do precision cardiology. A newer tool is the PREVENT calculator. What is it, and how does it differ from the older pooled equations?

Dr. Ernst Schaefer (25:00): The Pooled Cohort Equation came out in 2014; the PREVENT calculator was published in Circulation at the end of 2023. It adds body mass index and estimated GFR — a measure of kidney function. High BMI matters independently because it reflects insulin resistance, and a low eGFR under 60 is an important risk factor for premature heart disease. PREVENT is said to be about 75–80% accurate. But a recent JAMA paper suggests it underestimates risk — and a Harvard analysis estimated it would keep roughly 15 to 20 million Americans from being offered statins.

Dr. Ernst Schaefer (26:00): There are also huge geographic differences — two- to three-fold — in heart-disease mortality by state. New England does well; some Southern and Midwestern states don’t. That tells you environment and diet matter enormously, and our food industry hasn’t helped by packing foods with sugar, animal fat, and salt.

Dr. Regina Druz (27:00): These ultra-processed foods are strongly linked to cardiovascular disease, and those high-risk regions also have high rates of obesity, insulin resistance, and diabetes — the cardiometabolic picture. PREVENT is valuable because it broadens the variables to include BMI and kidney function, recognizing that cardiometabolic imbalance harms more than just the heart.

Dr. Ernst Schaefer (28:30): One more point: these calculators only count heart attacks, strokes, and deaths — not angioplasty or bypass. Better-educated populations who get better care are an example; education turns out to be an important predictor that isn’t in the model. So PREVENT may underestimate risk precisely in the populations at highest risk.

Dr. Regina Druz (29:00): A quick note: many of us are seeing patients arrive with self-ordered labs, which too often create confusion. That’s why we created HeartWell Toolkits — curated at-home blood and genetic markers focused on heart and brain health, available at the holisticheartcenters.com shop. Use code TESTING10 for 10% off and free shipping.

[30:30] Calcium Score, Soft Plaque & CT Angiography

Dr. Regina Druz (30:30): My favorite adjudicator is the MESA risk calculator, which adds the coronary calcium score to the pooled equation — and a cardiac CT lets me see what all those risk factors actually did to the coronaries. There’s been a lot of work bringing the inflammation hypothesis back, from Dr. Paul Ridker and Dr. Peter Libby’s groups, including the Reynolds Risk Score that incorporates high-sensitivity CRP. Your thoughts?

Dr. Ernst Schaefer (31:30): The Reynolds Risk Score is useful — about 70% accurate when you add CRP — though it was derived in a fairly healthy population. The MESA calculator uses the pooled equation plus calcium score. But largely from the calcium-scoring work, people now realize it’s not the calcified plaque that kills you — it’s the soft plaque. So if you really want to know what’s in your coronaries, you may need a CT angiogram, which is more complex and costly. The SCOT-HEART study and European data show soft plaque is what kills, and to convert soft plaque to stable calcified plaque, we need to be aggressive about lowering LDL.

Dr. Regina Druz (33:30): That’s a multi-pronged approach. A calcium score of zero is a great start — there’s only a small chance of plaque — but it doesn’t mean zero plaque; it means no calcified areas. I have patients with a zero score who still have soft plaque, and our holistic goal is to shift soft plaque toward stable, calcified plaque. What I love about MESA is that it translates all your inputs, including the calcium score, into a coronary artery age and aortic age — a powerful way for patients to see whether they’re aging faster or slower than expected. Vascular disease is the hallmark of aging: you can look phenomenal and still have arteries loaded with plaque.

[36:00] The Dyslipidemic Triad & Insulin Resistance

Dr. Regina Druz (36:00): Of all the lipid measurements, which is the single most atherogenic?

Dr. Ernst Schaefer (36:30): Working with Framingham since 1982, the answer was clearly small dense LDL. We also showed direct LDL is far better than calculated LDL, which is relatively worthless. Lp(a) was a bit less strong, and CRP matters mainly when quite high, with gender differences since women run higher. In MESA, Sarah Nomura and colleagues compared small dense LDL, ApoB, and LDL particle number in 2022 — small dense LDL was by far the most important. In the pooling project across Framingham, MESA, and ARIC, a small dense LDL over 50 carried about a 50% higher relative risk than under 25, even after adjusting for everything including total cholesterol.

Dr. Regina Druz (38:30): And much of that is driven by insulin resistance — you can have unremarkable standard lipids yet a high small dense LDL. If there’s one test every adult over 40 should know, it’s small dense LDL cholesterol.

Dr. Ernst Schaefer (39:30): Years ago Ron Krauss and Melissa Austin coined the “atherogenic triad”: high triglycerides, low HDL, and elevated small dense LDL — often alongside overweight and insulin resistance.

Dr. Regina Druz (40:00): A recent paper in the Journal of the American College of Cardiology rebranded it the dyslipidemic triad. Insulin resistance raises small dense LDL and lowers HDL — so those little balls become small, dense, and oxidation-prone, lodging in the arteries. And across the Framingham original, offspring, and third-generation cohorts, small dense LDL stays the most important lipid risk factor — true in men, women, and across ethnic groups in the ARIC data. That’s why we measure it directly on every patient, often through our HeartWell Toolkits.

[48:30] Lowering LDL: Statins, ALARA & Side Effects

Dr. Regina Druz (48:30): The number-one request we get is: can you help me lower my cholesterol without medication, or with as little as possible? Does lowering LDL actually make a difference?

Dr. Ernst Schaefer (49:00): It clearly does. The Silverman meta-analysis of about 49 trials, published in JAMA in 2016, showed roughly a 23% risk reduction for every 40 mg/dL drop in LDL, with even larger reductions from PCSK9 inhibitors. The pivotal JUPITER trial, run by Dr. Ridker, was stopped early because it was so favorable — overall about a 50% risk reduction, and if you got LDL under 70 and CRP under 1, risk fell 79%. Rosuvastatin 20 or 40 can lower LDL and small dense LDL by about 50%.

Dr. Regina Druz (50:00): An optimal LDL is generally under 70, or at least a 50% reduction from baseline. Doing that through lifestyle alone is possible but hard, and some patients need medication. The interesting thing about statins is that the lowest dose gives the biggest LDL drop.

Dr. Ernst Schaefer (51:00): That’s correct. Each time you double the dose, you only get about another 6% reduction. And statins do cause muscle problems — we see it every day. CoQ10 supplementation probably helps. There’s a reason rosuvastatin 80 mg and simvastatin 160 mg were dropped from trials: too much muscle toxicity. So start low, titrate up, and consider adding ezetimibe — rosuvastatin 20 plus ezetimibe 10 gives about a 70% reduction.

Dr. Regina Druz (52:30): That’s exactly our approach. At Holistic Heart Centers we use ALARA — as low as reasonably achievable — starting at low doses with supplement support and an intensive metabolic-health program, titrating only as needed. We also score statin-associated muscle symptoms using the ACC’s app before deciding whether a patient will benefit and how much they can take. Encouragingly, the European Society of Cardiology recently endorsed this same ALARA idea for patients who can’t tolerate full doses.

[54:30] The Best Mortality Markers & Closing

Dr. Ernst Schaefer (54:30): This surprised me. From the ARIC study — about 11,000 people followed at least 10 years — my mentor Bob Levy used to say the best predictor of disease is disease. It turns out NT-proBNP, a marker of heart failure, and troponin T, a marker of heart damage, predict total, cardiovascular, and stroke mortality with very large hazard ratios — three-, seven-, even tenfold for NT-proBNP. And controlling risk factors, especially high blood pressure, can lower them.

Dr. Regina Druz (56:00): It makes sense — coronary disease, if unmanaged, leads to heart failure or heart attack, so myocardial-damage markers track mortality. We don’t measure them on everyone, but strategically, to place patients on the continuum. And we shouldn’t forget HDL, the most abundant lipoprotein, which removes cholesterol from the artery wall. Ernie, thank you so much for being here — I hope our listeners come away with a new understanding of LDL and the markers that truly matter.

Dr. Ernst Schaefer (59:30): Thank you. Thank you.

Frequently Asked Questions

What is small dense LDL, and why is it more dangerous than regular LDL cholesterol?

Small dense LDL refers to the smaller, denser subset of LDL cholesterol particles. Although they carry only about 30% of the cholesterol, they make up roughly 70–80% of the particles, and they slip into the artery wall far more easily than larger, buoyant LDL. They also linger in the bloodstream much longer — about four days versus two — which gives them more time to become oxidized and be swept up by immune cells, forming plaque. In large studies across Framingham, MESA, and ARIC, small dense LDL was the single most important lipid risk factor, and a level above 50 carried about 50% higher risk than a level under 25, even after accounting for total cholesterol. Crucially, it’s driven heavily by insulin resistance, so you can have a normal-looking standard panel and still run a high small dense LDL — which is why measuring it directly is so valuable.

If my standard cholesterol panel looks normal, could I still be at risk?

Yes. A routine panel — total cholesterol, LDL, HDL, triglycerides — can look reassuring while more powerful, risk-enhancing markers tell a different story. Insulin resistance can raise small dense LDL and lower HDL without dramatically changing the standard numbers, and genetically determined Lipoprotein(a) isn’t on a basic panel at all. That’s why advanced testing can be an eye-opener: directly measured LDL, small dense LDL, ApoB (a precise count of atherogenic particles), Lp(a), and markers of oxidation and inflammation give a fuller picture. None of this is a reason to panic over a single value; it’s a reason to look deeper with your physician and interpret the whole pattern in the context of your blood pressure, metabolic health, family history, and, where appropriate, a calcium score or imaging.

What are ApoB and Lp(a), and should I have them tested?

ApoB (apolipoprotein B) is the protein on the surface of LDL and related particles, and because there’s one ApoB per particle, it’s essentially a precise count of how many atherogenic particles you have — increasingly viewed as a stronger predictor than standard cholesterol numbers. Lipoprotein(a), or Lp(a), is a largely genetic particle that accepts oxidized phospholipids and is an independent risk factor; most people never have it checked, yet it can meaningfully change risk. Many lipid experts now suggest measuring ApoB as part of a thorough assessment, and checking Lp(a) at least once in adulthood since it’s mostly set by genetics. What you do with the results — lifestyle, targeted nutrition, or medication — should be individualized with your physician rather than driven by any single number.

Do I have to take a high-dose statin to lower my risk?

Not necessarily. A key point from this conversation is that the lowest statin dose produces the biggest LDL reduction, while each doubling of the dose adds only about 6% more — often with more side effects, including real statin-associated muscle symptoms. A “start low, go slow” strategy — sometimes called as-low-as-reasonably-achievable — pairs a modest dose with lifestyle and metabolic-health work, and can add a second agent such as ezetimibe to reach the target with less medication. Reasonable goals are an LDL under about 70 or at least a 50% reduction, but the right plan depends on your overall risk, not a single number. Any decision to start, adjust, or stop a statin should be made with your own physician, who can also assess muscle symptoms and consider supports like CoQ10.

Show Notes & Resources

Guest: Dr. Ernst J. Schaefer, MD

Dr. Ernst J. Schaefer is a lipidologist and the Chief Medical Officer and co-founder of Boston Heart Diagnostics, a laboratory specializing in advanced cardiovascular testing. Trained at Mount Sinai, with research at Albert Einstein and Rockefeller and a long academic career at Tufts University, he has worked with the Framingham Heart Study since 1982. He is a leading authority on LDL subfractions, ApoB, Lp(a), and the central role of small dense LDL in atherosclerosis.

Boston Heart Diagnostics: bostonheartdiagnostics.com

Resources Mentioned in This Episode

Boston Heart Diagnostics — advanced cardiovascular and lipid testing (bostonheartdiagnostics.com)
Framingham Heart Study — the foundational study of cardiovascular risk factors (original, offspring, and third-generation cohorts)
ASCVD Risk Estimator (Pooled Cohort Equations, ACC/AHA, 2014) — ~65% accurate
PREVENT calculator (American Heart Association, Circulation 2023) — adds BMI and kidney function (eGFR)
MESA risk calculator — pooled equation plus coronary calcium score, with coronary artery age
Reynolds Risk Score — incorporates high-sensitivity CRP
JUPITER trial (rosuvastatin) and the Silverman LDL-lowering meta-analysis (JAMA, 2016)
ARIC study (Atherosclerosis Risk in Communities) — NT-proBNP and troponin T as mortality markers
ACC ASCVD Risk / statin-intolerance (SAMS) app
Holistic Heart University — courses including the Statin Overprescribing Solution (use code OWNER20 for 20% off annual)
HeartWell Toolkits — at-home advanced lipid and metabolic panels (use code TESTING10 for 10% off and free shipping)
For clinicians: Practice Power Hour coaching with Holistic Heart Centers (use code DOC10 for 10% off)

Holistic Heart Centers

holisticheartcenters.com
HeartWell.ai — AI-powered cardiovascular risk assessment
Address: 55 Bryant Avenue, Suite #6, Roslyn, NY 11576
Phone: 877-511-5166
YouTube: @reginadruzmd
Instagram: @dr.reginadruz
Podcast: Own Your Heart Health — available on Apple Podcasts, Spotify, and all major platforms

Listen & Subscribe

If you enjoyed this episode, please rate and review us on your favorite platform — it helps more people find the show.

Apple Podcasts Spotify YouTube